HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

sipoglitazar

an antidiabetic agent

Also Known As:

3-(3-ethoxy-1-((4-((2-phenyl-1,3-thiazol-4-yl)methoxy)phenyl)methyl)pyrazol-4-yl)propanoic acid

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Propionates: 988
      - sipoglitazar: 1
- Sulfur Compounds: 278
  - Thiazoles: 392
    - sipoglitazar: 1
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Propionates: 988
      - sipoglitazar: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - sipoglitazar: 1

Experts

1.	Danhof, Meindert: 1 article (04/2014)
2.	DeJongh, Joost: 1 article (04/2014)
3.	Scott, Graham: 1 article (04/2014)
4.	Stringer, Frances: 1 article (04/2014)

Related Diseases

1.

Type 2 Diabetes Mellitus (MODY)

04/01/2014 - "The current PK-PD analysis confirms that UGT2B15 genotype is a major determinant for differences in FPG and HbA1c response to sipoglitazar treatment between Type 2 Diabetes mellitus patients, due to related differences in drug exposure. "
04/01/2014 - "Efficacy and safety of sipoglitazar compared to placebo were assessed in Type 2 Diabetes Mellitus patients in two Phase II randomized, double-blind studies (sipoglitazar once daily: 8, 16, 32, or 64 mg; sipoglitazar twice daily: 16 or 32 mg; rosiglitazone 8 mg once daily and placebo for 13 weeks; n = 780). "

Related Drugs and Biologics

1.	Rosiglitazone (Avandia)